Mersana Therapeutics, Inc. (MRSN)
Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN)
29.08
+0.04 (0.14%)
Inactive · Last trade price on Jan 5, 2026

Mersana Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jan '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1451772806164581,832
Market Cap Growth
-42.03%-36.91%-54.55%34.39%-74.97%604.37%
Enterprise Value
91.2970.67104.6371.74318.71,593
Last Close Price
29.0835.7558.00146.50155.50665.25
PE Ratio
--2.55-1.57-2.69-2.58-18.61
PS Ratio
4.364.367.6023.1810662.102212.40
PB Ratio
--18.587.596.693.778.03
P/TBV Ratio
-2.43-18.437.305.963.617.17
P/FCF Ratio
--2.14-1.64-11.95-3.26-24.37
P/OCF Ratio
--2.15-1.66-12.48-3.28-24.52
EV/Sales Ratio
2.751.742.8413.997411.611924.33
EV/EBITDA Ratio
--0.99-0.59-1.83-1.90-18.29
EV/EBIT Ratio
--0.96-0.58-1.82-1.89-18.08
EV/FCF Ratio
--0.86-0.61-7.21-2.27-21.20
Debt / Equity Ratio
-0.04-3.010.910.390.310.07
Debt / EBITDA Ratio
-0.04-0.40-0.19-0.18-0.23-0.19
Debt / FCF Ratio
-0.03-0.35-0.20-0.70-0.27-0.22
Asset Turnover
0.320.220.130.100.000.00
Quick Ratio
1.312.163.293.393.748.50
Current Ratio
1.392.193.363.493.978.62
Return on Equity (ROE)
203.00%-505.36%-266.26%-191.03%-97.23%-57.47%
Return on Assets (ROA)
-64.99%-39.32%-64.12%-75.41%-70.43%-46.26%
Return on Invested Capital (ROIC)
557.70%571.87%2281.81%2488.00%1772.42%1197.80%
Return on Capital Employed (ROCE)
-132.60%-59.96%-88.68%-101.53%-84.01%-53.91%
Earnings Yield
-48.20%-39.16%-63.79%-37.20%-38.75%-5.37%
FCF Yield
-51.15%-46.68%-61.08%-8.37%-30.68%-4.10%
Buyback Yield / Dilution
--3.58%-33.95%-24.88%-9.94%-12.60%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q